Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Bob Farrell Email

<< Previous

Bullboard Posts

Next >>

Comment by polygraph46on Apr 28, 2021 1:03am

232 Views

Post# 33080481

RE:Bob Farrell Email

Re: Farrell Email. Bailey, what I would like to know, is this an official communication from

the President of the Company (Farrell) to you and others in the Conclave touting the benefits of

massive share consolidation? Like, if that is so, then why has it not been released as NEWS by the

Company? And then you, in mouthpuppet fashion come out from behind the curtain

with snippets? Who is this information supposed to reach? A special group of onside pumpers for

seep, or all retail holders of this security as well as the Venture Exchange? pg

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec